Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Esperion Therapeutics Inc shares valued at $4,868 were sold by Looker Benjamin on Jan 20 ’26. At $2.88 per share, Looker Benjamin sold 1,689 shares. The insider’s holdings dropped to 384,216 shares worth approximately $1.22 million following the completion of this transaction.
Also, Looker Benjamin purchased 1,689 shares, netting a total of over 4,867 in proceeds.
Before that, Koenig Sheldon L. had sold 48,244 shares from its account. In a trade valued at $177,200, the President and CEO traded Esperion Therapeutics Inc shares for $3.67 each. Upon closing the transaction, the insider’s holdings decreased to 48,244 shares, worth approximately $4.66 million.
As published in their initiating research note from Piper Sandler on November 25, 2025, Esperion Therapeutics Inc [ESPR] has been an Overweight and the price target has been revised to $9. Analysts at Goldman started covering the stock with ‘”a Neutral”‘ outlook in a report released in mid December. As of December 17, 2024, Cantor Fitzgerald has initiated its “an Overweight” rating for ESPR. Earlier on June 20, 2024, BofA Securities downgraded its rating. Their new recommendation was “an Underperform” for ESPR stock which previously was a “a Neutral”.
Analyzing ESPR Stock Performance
On last trading session, Esperion Therapeutics Inc [NASDAQ: ESPR] rose 6.38% to $3.17. The stock’s lowest price that day was $2.97, but it reached a high of $3.2 in the same session. During the last five days, there has been a drop of approximately -1.86%. Over the course of the year, Esperion Therapeutics Inc shares have jumped approximately 47.44%.
Is Esperion Therapeutics Inc subject to short interest?
Stocks of Esperion Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 5.2 million shares to 33.93 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 28.73 million shares. A jump of 15.34% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.62 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.62.
Which companies own the most shares of Esperion Therapeutics Inc (ESPR)?
In terms of Esperion Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 9 in the next 12 months, up nearly 202.01% from the previous closing price of $2.98. Analysts anticipate Esperion Therapeutics Inc stock to reach 9 by 2026, with the lowest price target being 9. In spite of this, 8 analysts ranked Esperion Therapeutics Inc stock as Buy at the end of 2026.
